A Versatile, Modular Approach To Building Customized, Site-specifically Conjugated ADCs Using SMARTag™ Technology

Summary: Antibody-Drug Conjugates (ADCs) are a class of bioconjugates that combine the target specificity of an antibody with the high potency of a synthetic small molecule, which can be a useful tool for targeted therapy. The optimal ADC will leverage the innate characteristics of its distinct components to create a compound with an expanded therapeutic window, exhibiting increased potency with reduced toxicity and minimal side effects. One of the challenges in ADC is to generate uniform site-specific ADCs, which entails controlling the conjugate location on the protein peptide backbone.

Download the Poster